Skip to main content

Understanding Abnormal Earnings

At the heart of every valuable company lies a simple truth: it earns more than what investors require to justify their capital. A retailer that reinvests $100 million in inventory expects to generate profits that exceed the cost of that capital. A pharmaceutical firm with a patent-protected drug generates earnings far above what a typical business would earn on the same invested capital. These "extra" earnings—abnormal earnings—are not a minor phenomenon. They are the entire source of value creation above book value. Understanding abnormal earnings is essential to mastering the Residual Income Model.

Quick Definition​

Abnormal earnings (also called excess earnings or economic profit) are the earnings a company generates above what is required given its cost of equity capital. Mathematically, abnormal earnings in year t equal net income minus the cost of equity capital applied to beginning-of-period book value: Abnormal Earnings = Net Income − (Cost of Equity × Beginning Book Value). Positive abnormal earnings indicate value creation; negative abnormal earnings indicate value destruction.

Key Takeaways​

  • Abnormal earnings measure whether a company's profits exceed the returns investors demand, distinguishing value-creating enterprises from mediocre ones.
  • A company earning 15% on equity when investors demand only 10% is generating substantial abnormal earnings; one earning 8% is destroying value.
  • The durability of abnormal earnings—how long competitive advantages sustain superior returns—is the primary determinant of intrinsic value in RIM.
  • Abnormal earnings decline over time as competitive pressures erode advantages, a crucial assumption in all long-term valuation models.
  • Companies with durable competitive moats (brands, network effects, switching costs) sustain abnormal earnings longer than those in commoditized industries.
  • Understanding abnormal earnings reframes investment analysis from "how much profit does this company make?" to "how much better than fair return does it generate?"

Why Accounting Earnings Alone Tell an Incomplete Story​

The income statement reports net income, the profit a company generated during a period. This number is crucial but incomplete from a valuation perspective. A company might report $50 million in annual net income, which sounds profitable. But if shareholders have invested $500 million in equity to generate that $50 million, they're earning a 10% return. If the market demands a 12% return for that level of risk, the company is actually destroying value—generating returns below cost of capital.

This is where abnormal earnings bridge the gap between accounting and economics. Accounting profit tells you what was earned. Abnormal earnings tells you whether that profit was enough.

Consider two companies, each with $1 billion in book value and $100 million in annual net income (a 10% return on equity):

Company A operates in a competitive, commoditized market. Investors require 12% returns given the business risk. Abnormal earnings = $100M − (12% × $1,000M) = $100M − $120M = −$20M. The company is destroying shareholder value despite being profitable.

Company B has a strong brand and competitive moat. Investors require only 8% returns given its stability. Abnormal earnings = $100M − (8% × $1,000M) = $100M − $80M = +$20M. The company is creating $20 million in annual value for shareholders.

Same accounting profit. Opposite economic realities. This distinction is why abnormal earnings are central to rational valuation.

The Return on Equity (ROE) Connection​

Abnormal earnings are intimately linked to Return on Equity (ROE). ROE measures how much profit a company generates per dollar of shareholder capital. If a company has $500 million in equity and earns $50 million, its ROE is 10%.

Abnormal earnings can be expressed as:

Abnormal Earnings = Book Value × (ROE − Cost of Equity)

This formula reveals the economics elegantly. If ROE exceeds cost of equity, the company is generating positive abnormal earnings. If ROE equals cost of equity, abnormal earnings are zero (fair value). If ROE is below cost of equity, the company is destroying value.

A company with 20% ROE and 12% cost of equity generates 8% abnormal earnings per dollar of book value. That 8% spread is the economic profit margin—the excess return that justifies why the stock trades above book value.

This perspective reframes competitive advantage. Instead of asking "which companies are profitable?" ask "which companies earn returns substantially above their cost of capital?"

Sustainability and Mean Reversion​

Here lies the critical insight that makes valuation possible: abnormal earnings don't persist forever. Eventually, competitive pressures erode them.

A pharmaceutical company with a blockbuster drug might earn 25% ROE while competitors are stuck at 12%. That 13% abnormal return is remarkable and valuable. But when the patent expires, competitors enter, and ROE reverts toward cost of equity. Value creation accelerates until the competitive advantage erodes, then decelerates as abnormal earnings shrink.

The RIM framework builds this reversion into the valuation explicitly. Rather than assuming perpetual abnormal earnings (a common error), you forecast that they:

  1. Remain elevated for a defined explicit period (typically 5–10 years) as the competitive moat holds
  2. Gradually decline as new competition enters and margins compress
  3. Converge to zero at perpetuity (or remain modest if durable advantages persist)

This is why forecasting the durability of competitive advantages is the highest-leverage decision in RIM valuation. A company with a 10-year competitive moat is worth far more than an identical company with only a 5-year advantage.

Measuring Abnormal Earnings: Practical Framework​

To calculate abnormal earnings for a specific company, you need:

1. Net Income — from the income statement, adjusted for unusual items 2. Book Value of Equity — typically from the balance sheet at the beginning of the period 3. Cost of Equity — the required return for shareholders (estimated via CAPM or other methods)

The formula is straightforward:

Year t Abnormal Earnings = NI(t) − Cost of Equity × Book Value(t−1)

For example, consider a company with:

  • Beginning book value: $400 million
  • Net income year 1: $60 million
  • Cost of equity: 12%

Abnormal earnings = $60M − (0.12 × $400M) = $60M − $48M = $12M

The company earned $60 million, but shareholders required $48 million in returns. The $12 million excess is abnormal earnings—pure value creation.

Industry Variation: Where Abnormal Earnings Are Largest​

Abnormal earnings vary dramatically across industries based on competitive structure and barriers to entry.

High abnormal earnings industries:

  • Technology/software (switching costs, network effects, scale)
  • Healthcare/pharmaceuticals (patents, regulatory barriers)
  • Luxury goods (brand value, pricing power)
  • Telecommunications (infrastructure capital, high switching costs)
  • Payment processors (network effects, incumbent advantages)

Low/negative abnormal earnings industries:

  • Retail (commoditized, intense competition)
  • Airlines (commodity service, high capital intensity, cyclical)
  • Supermarkets (thin margins, local competition)
  • Utilities (regulated returns, limited upside)
  • Metals and mining (commodity pricing, high cyclicality)

This variation explains why investors should be willing to pay premiums for companies in advantage-rich industries and demand discounts for commodity businesses.

Real-World Example: Apple vs. Delta Air Lines​

Apple (Technology/Ecosystem)

Apple's fiscal 2023 results show:

  • Book value of equity: ~$63 billion
  • Net income: ~$97 billion
  • Cost of equity (estimated): ~8% (lower due to stability and scale)
  • Abnormal earnings = $97B − (8% × $63B) = $97B − $5B = ~$92B

Apple's abnormal earnings are enormous—$92 billion annually—because it generates extraordinary returns (154% ROE) far exceeding investor requirements. This is why Apple's stock trades at such a premium to book value. The market is paying for decades of abnormal earnings from its ecosystem lock-in, brand power, and pricing control.

Delta Air Lines (Cyclical Commodity)

Delta's fiscal 2023 results show:

  • Book value of equity: ~$8 billion
  • Net income: ~$4 billion
  • Cost of equity (estimated): ~9% (higher due to cyclicality and leverage)
  • Abnormal earnings = $4B − (9% × $8B) = $4B − $0.7B = ~$3.3B

Delta generates positive but modest abnormal earnings because it operates in a competitive, cyclical industry with thin margins. The airline earns returns that slightly exceed cost of equity but not dramatically. This explains why airlines trade close to book value and rarely earn the premium valuations of technology companies.

Common Mistakes with Abnormal Earnings​

Assuming perpetual abnormal earnings. The most dangerous error is assuming a company will generate the same abnormal earnings forever. Competition exists. Technology disrupts. Competitive moats erode. A company earning 20% ROE today might earn 14% in five years and 11% in ten years as competitors catch up. Your forecast should reflect this reversion.

Confusing ROE with abnormal earnings. A company with 12% ROE creating value depends entirely on cost of equity. If cost of equity is 10%, the 12% ROE creates abnormal earnings. If cost of equity is 15%, the same 12% ROE destroys value. Never evaluate abnormal earnings without accounting for the cost of capital.

Ignoring quality of earnings. The income statement can be manipulated. Abnormal earnings based on distorted net income are useless. Adjust net income for one-time items, changes in accounting estimates, and cash flow sustainability. Abnormal earnings should reflect sustainable, repeatable profit generation.

Missing competitive dynamics. Strong abnormal earnings attract competitors. Your valuation should explicitly model how competition will compress those earnings. If you don't explain why competitors haven't already entered and reduced abnormal earnings, your forecast is probably too optimistic.

Underestimating cost of equity. Abnormal earnings are calculated net of cost of equity. A lower cost of equity assumption makes abnormal earnings appear higher. Be rigorous about cost of equity estimation; don't bias it downward to inflate valuation.

Frequently Asked Questions​

Q: Can a company have negative abnormal earnings and still be valuable? A: Yes. Negative abnormal earnings in early years can reflect growth investments that generate returns above cost of equity later. Amazon famously had low or negative abnormal earnings for years while building infrastructure for future profitability. What matters is the present value of the entire stream of future abnormal earnings.

Q: How do I forecast when abnormal earnings will decline? A: This depends on competitive dynamics and barriers to entry. High-moat businesses (software, pharma, brands) sustain abnormal earnings 10–15+ years. Commoditized businesses see them erode within 3–5 years. Study the competitive structure: can new entrants easily replicate the business? Can incumbents improve? Answers inform your forecast.

Q: Is high ROE always good? A: High ROE is only good if it exceeds cost of equity and is sustainable. A cyclical company with 25% ROE during a boom might only earn 8% average-cycled ROE. A company with 20% ROE achieved through leverage might face financial distress if business slows. Assess quality and sustainability.

Q: Should I forecast abnormal earnings to immediately revert to zero? A: No. Immediate reversion ignores competitive advantages. Most companies deserve a forecast period of 5–10 years where abnormal earnings remain elevated, then a fade period where they decline toward zero. The length depends on competitive moat durability.

Q: How does abnormal earnings connect to free cash flow valuation? A: Both approach the same question (what's the company worth?) from different angles. Free cash flow captures cash available to investors. Abnormal earnings captures economic profit. Properly calculated, they produce the same intrinsic value. RIM offers a more direct path when accounting-based forecasts are more reliable than cash flow projections.

  • Return on Invested Capital (ROIC) — A similar concept to ROE but calculated on all invested capital (equity plus debt), useful for analyzing capital allocation efficiency across the entire business, not just equity.
  • Economic Value Added (EVA) — A trademarked cousin of abnormal earnings that measures value creation from operations, often used in performance management and incentive structures within large corporations.
  • Competitive Moat — The durable advantages that allow companies to sustain abnormal earnings, including brand strength, switching costs, network effects, and scale economies.
  • Mean Reversion — The tendency of abnormal earnings to decline over time as competitive pressures compress margins and returns, a key assumption in long-term valuation models.
  • Cost of Equity — The required return shareholders demand, which determines the threshold above which earnings are "abnormal" and where below it destroys value.

Summary​

Abnormal earnings are the bridge between accounting profit and economic value. They measure the excess returns a company generates above its cost of capital. A company earning 15% ROE when investors demand only 10% creates abnormal earnings of 5% on its book value—pure value creation. These abnormal earnings, when projected into the future and discounted, form the entire basis of intrinsic value in the Residual Income Model.

The critical insight is that abnormal earnings don't persist. Competitive pressures erode them. Your valuation must forecast when and how fast that erosion occurs. Companies with durable competitive moats sustain abnormal earnings longer, justifying premium valuations. Those in commoditized industries see abnormal earnings decline quickly.

Understanding abnormal earnings forces a shift in how you think about investment. Instead of asking "How much profit does this company make?" ask "How much better than fair return does it generate?" That question focuses your analysis on the only thing that matters: competitive advantage and its sustainability.

Next Steps​

The cost of equity is the denominator that determines whether earnings are abnormal. Learn how to estimate and apply it correctly in the next article: Cost of Equity in RIM.